Tatyana Vlaykova
Trakia University, Stara Zagora, Bulgaria
Title: Matrix metalloproteinases in development of COPD
Biography
Biography: Tatyana Vlaykova
Abstract
The main pathological features of COPD are abnormal chronic inflammation in the airways, development of extensive tissue remodeling and local and systemic oxidative stress. A growing body of evidence indicates that matrix metalloproteinases (MMPs) play a pivotal role in remodeling of the small airways and particularly of the terminal bronchioles in lungs of COPD patients.
In the current review we aim to present our results concerning the possible role of several functional SNPs in promoter regions of MMPs (MMP-1607 1G>2G, [rs1799750], MMP2–1306C>T [rs243865], MMP3-1171 5A>6A, [rs3025058], MMP7-181A>G [rs11568818], and MMP12-82A>G [rs2276109]) and serum levels of those proteinases in development of COPD in Bulgarian population from the central region of the country.
The performed case-control studies showed that MMP2–1306C>T, MMP7-181A>G and MMP12-82 A>G may affect the risk for COPD, while the other promoter SNPs did not have any associations with COPD. The old carriers (≥65 years) of minor T allele genotypes (CT+TT) of MMP2–1306C>T SNP had higher risk than CC carriers (OR=4.54, 95%CI:1.20-17.24, gender and age adjusted, p=0.026). Concerning MMP7-181A>G SNP, we observed that the minor G allele genotypes (AG+GG) were more frequent in COPD than AA genotype among the younger individuals (OR=2.30, 95%CI:1.00-5.27, gender and age adjusted, p=0.050). Moreover, patients with minor G allele genotypes developed COPD significantly early that those with AA genotype (61.01±10.11 vs. 64.87±9.00 years, p=0.032). The minor G allele of MMP12-82 A>G SNP appeared to be a protective factor for COPD as the carriers of G allele genotypes had about 2-fold lower risk for the disease (OR=0.446, 95%CI:0.25-0.80, adjusted for gender and age, p=0.007).
The serum levels of MMP-1 and MMP-7 did not differ significantly between patients and controls, while the MMP-3 appeared to be higher in patients with COPD (p=0.020), and MMP-2 was higher in female COPD patients than healthy women (p=0.043)